Passage Bio Inc. (PASG): Price and Financial Metrics
PASG Price/Volume Stats
| Current price | $1.15 | 52-week high | $1.79 |
| Prev. close | $1.20 | 52-week low | $0.58 |
| Day low | $1.12 | Volume | 284,200 |
| Day high | $1.20 | Avg. volume | 369,070 |
| 50-day MA | $1.36 | Dividend yield | N/A |
| 200-day MA | $0.93 | Market Cap | 70.85M |
PASG Stock Price Chart Interactive Chart >
Passage Bio Inc. (PASG) Company Bio
Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.
Latest PASG News From Around the Web
Below are the latest news stories about PASSAGE BIO INC that investors may wish to consider to help them evaluate PASG as an investment opportunity.
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)PHILADELPHIA, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted an inducement award to a new employee. Passage Bio granted options to purchase 10,400 shares of common stock to this employee as material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise pric |
Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business HighlightsOn track to present initial safety and biomarker data from three Cohort 1 patients in global Phase 1/2 upliFT-D trial of PBFT02 for the treatment of patients with frontotemporal dementia (FTD) with granulin mutations (GRN) in Q4 2023Expect to report initial safety and biomarker data from Dose 3 patients in global Phase 1/2 Imagine-1 clinical trial for gangliosidosis (GM1) in mid-2024Robust balance sheet to support achievement of meaningful clinical milestones, with cash runway into Q4 2025 PHILA |
Passage Bio to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology ConferencePHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that William Chou, M.D., president and chief executive officer, will participate in a fireside chat at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference on Monday, November 6, 2023 at 2:30 p.m. ET. A live webcast of the event will be available on |
Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PHILADELPHIA, Oct. 20, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted inducement awards to new employees. Passage Bio granted options to purchase 50,000 shares of common stock to these employees as material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price |
Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines ConferencePHILADELPHIA, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that William Chou, M.D., president and chief executive officer, will participate in a fireside chat at Chardan’s 7th Annual Genetic Medicines Conference on Monday, October 2, 2023 at 5:00 p.m ET. A live webcast of the event will be available on the Investors & Media |
PASG Price Returns
| 1-mo | -16.06% |
| 3-mo | 27.93% |
| 6-mo | 71.90% |
| 1-year | 17.94% |
| 3-year | -93.35% |
| 5-year | N/A |
| YTD | 13.86% |
| 2023 | -26.81% |
| 2022 | -78.27% |
| 2021 | -75.17% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...